Indeed, many studies have reported increased efficacy in generating an immune response against a variety of tumours using anti-PD-1/PD-L1 ICBs with different oncolytic viruses, including various DNA and RNA viruses, which are reviewed elsewhere [104]. The gene discussed is CD274; the disease is neoplasm.